Médecine

Paramédical

Autres domaines


S'abonner

Medical therapy at discharge in patients admitted for acute coronary syndrome: Data of the French MONICA population registers - 09/01/21

Doi : 10.1016/j.acvdsp.2020.10.005 
S. Huo Yung Kai 1, 2, , M. Moitry 3, 4, K. Biasch 3, M. Montaye 5, J. Dallongeville 5, J. Ferrières 2, 6
1 Public Health, CHU Toulouse 
2 Epidemiology, Health Economics and Public Health, UMR1027, INSERM, University Paul Sabatier, Toulouse 
3 Epidemiology and Public Health, University of Strasbourg 
4 Public Health, University Hospital of Strasbourg, Strasbourg 
5 U1167-RID-AGE-Risk factors and molecular determinants of aging-related diseases, University of Lille, Inserm, University Hospital of Lille, Institute Pasteur of Lille, Lille 
6 Cardiology, University Hospital of Toulouse, Toulouse, France 

Corresponding author.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Résumé

Background

Secondary prevention is as important as primary management in the care of patients with acute coronary syndrome (ACS).

Aim

To describe prescription at discharge in patients admitted for an ACS in 3 population registers.

Methods

Patients aged 35–74 years old admitted for ACS in the regions covered by the French MONICA registers (Bas-Rhin, BR; Haute-Garonne, HG; Urban community of Lille, UCL) between 01/10/2015 and 31/03/2016, alive at discharge, were included. Prescription rates for dual antiplatelet therapy (DAPT: aspirin+ticagrelor/clopidogrel/prasugrel), b-blockers (BB), angiotensin-converting enzyme inhibitors (ACEI)/angiotensin II receptor blockers (ARBs), statins, and the combination of the 4 drugs were calculated. Statistical differences were assessed using logistic regressions adjusted for region, age, sex, ST-elevation, type of revascularisation, cardiovascular risk factors, and comorbidities.

Results

A total of 1439 patients were included (77.6% men, median age 61.1). Prescription rates at discharge were 87% for DAPT, 85% for BB, 75% for ACEI/ARBs, 92% for statins, and 57% for all 4 drugs. For patients treated with percutaneous transluminal coronary angioplasty (PCTA), DAPT prescription was less frequent in HG compared to BR (Table 1). BB and ACEI/ARBs were less often prescribed in HG than in BR, and when a conservative treatment (CT: no PCTA nor coronary artery bypass grafting, CABG) was chosen over PCTA. Their prescription was more frequent in patients with ST-elevation. Prescription of statins was less frequent for patients with CT compared to patients with PCTA. All 4 drugs were less prescribed in the HG region than in BR. This was also observed for patients with CT or CABG compared to those with PCTA. Conversely, patients with ST-elevation were more frequently discharged with all 4 drugs compared to patients with no ST-elevation.

Conclusion

Prescriptions at discharge in patients admitted for an ACS still vary and need to be harmonised.

Le texte complet de cet article est disponible en PDF.

Plan


© 2020  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 13 - N° 1

P. 7 - janvier 2021 Retour au numéro
Article précédent Article précédent
  • Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of randomized trials relevant in routine clinical practice?
  • J. Ferrières, V. Bataille, E. Puymirat, F. Schiele, T. Simon, N. Danchin
| Article suivant Article suivant
  • Post-infectious myocardial Infarction: Does percutaneous coronary intervention improve outcomes? A propensity-score matched analysis
  • A. Putot, F. Chagué, P. Manckoundia, D. Brunet, J. Beer, Y. Cottin, M. Zeller

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.